BACKGROUND: Transcatheter tricuspid valve intervention became an option for pacemaker lead-associated tricuspid regurgitation. This study investigated the progression of tricuspid regurgitation (TR) in patients with or without pre-existing right ventricular dilatation (RVD) undergoing pacemaker implantation. METHODS: Patients were included if they had implantation of transtricuspid pacemaker lead and completed echocardiography before and after implantation. The cohort was divided in patients with and without RVD (cut-off basal RV diameter ≥ 42 mm). TR was graded in none/mild, moderate, and severe. Worsening of one grade was defined as progression. Survival analyses were plotted for 10 years. RESULTS: In total, 990 patients were analyzed (24.5% with RVD). Progression of TR occurred in 46.1% of patients with RVD and in 25.6% of patients without RVD (P < 0.001). Predictors for TR progression were RV dilatation (OR 2.04; 95% CI 1.27-3.29; P = 0.003), pre-existing TR (OR 4.30; 95% CI 2.51-7.38; P < 0.001), female sex (OR 1.68; 95% CI 1.16-2.43; P = 0.006), single RV lead (OR 1.67; 95% CI 1.09-2.56; P = 0.018), mitral regurgitation (OR 2.08; 95% CI 1.42-3.05; P < 0.001), and enlarged left atrium (OR 1.98; 95% CI 1.07-3.67; P = 0.03). Survival-predictors were pacemaker lead-associated TR (HR 1.38; 95% CI 1.04-1.84; P = 0.028), mitral regurgitation (HR 1.34; 95% CI 1.02-1.77; P = 0.034), heart failure (HR 1.75; 95% CI 1.31-2.33; P < 0.001), kidney disease (HR 1.62; 95% CI 1.25-2.11; P < 0.001), and age ≥ 80 years (HR 2.84; 95% CI 2.17-3.71; P < 0.001). CONCLUSIONS: Patients with RVD receiving pacemaker suffered from increased TR progression, leading to decreased survival.
BACKGROUND: Transcatheter tricuspid valve intervention became an option for pacemaker lead-associated tricuspid regurgitation. This study investigated the progression of tricuspid regurgitation (TR) in patients with or without pre-existing right ventricular dilatation (RVD) undergoing pacemaker implantation. METHODS:Patients were included if they had implantation of transtricuspid pacemaker lead and completed echocardiography before and after implantation. The cohort was divided in patients with and without RVD (cut-off basal RV diameter ≥ 42 mm). TR was graded in none/mild, moderate, and severe. Worsening of one grade was defined as progression. Survival analyses were plotted for 10 years. RESULTS: In total, 990 patients were analyzed (24.5% with RVD). Progression of TR occurred in 46.1% of patients with RVD and in 25.6% of patients without RVD (P < 0.001). Predictors for TR progression were RV dilatation (OR 2.04; 95% CI 1.27-3.29; P = 0.003), pre-existing TR (OR 4.30; 95% CI 2.51-7.38; P < 0.001), female sex (OR 1.68; 95% CI 1.16-2.43; P = 0.006), single RV lead (OR 1.67; 95% CI 1.09-2.56; P = 0.018), mitral regurgitation (OR 2.08; 95% CI 1.42-3.05; P < 0.001), and enlarged left atrium (OR 1.98; 95% CI 1.07-3.67; P = 0.03). Survival-predictors were pacemaker lead-associated TR (HR 1.38; 95% CI 1.04-1.84; P = 0.028), mitral regurgitation (HR 1.34; 95% CI 1.02-1.77; P = 0.034), heart failure (HR 1.75; 95% CI 1.31-2.33; P < 0.001), kidney disease (HR 1.62; 95% CI 1.25-2.11; P < 0.001), and age ≥ 80 years (HR 2.84; 95% CI 2.17-3.71; P < 0.001). CONCLUSIONS:Patients with RVD receiving pacemaker suffered from increased TR progression, leading to decreased survival.
Authors: Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Lee A Fleisher; Hani Jneid; Michael J Mack; Christopher J McLeod; Patrick T O'Gara; Vera H Rigolin; Thoralf M Sundt; Annemarie Thompson Journal: J Am Coll Cardiol Date: 2017-03-15 Impact factor: 24.094
Authors: Maurizio Taramasso; Hannes Alessandrini; Azeem Latib; Masahiko Asami; Adrian Attinger-Toller; Luigi Biasco; Daniel Braun; Eric Brochet; Kim A Connelly; Paolo Denti; Florian Deuschl; Andrea Englmeier; Neil Fam; Christian Frerker; Jörg Hausleiter; Dominique Himbert; Edwin C Ho; Jean-Michel Juliard; Ryan Kaple; Felix Kreidel; Karl-Heinz Kuck; Marco Ancona; Alexander Lauten; Philipp Lurz; Michael Mehr; Tamin Nazif; Georg Nickening; Giovanni Pedrazzini; Alberto Pozzoli; Fabien Praz; Rishi Puri; Josep Rodés-Cabau; Ulrich Schäfer; Joachim Schofer; Horst Sievert; Kolja Sievert; Gilbert H L Tang; Felix C Tanner; Alec Vahanian; John G Webb; Stephan Windecker; Ermela Yzeiray; Michel Zuber; Francesco Maisano; Martin B Leon; Rebecca T Hahn Journal: JACC Cardiovasc Interv Date: 2018-12-26 Impact factor: 11.195
Authors: Helmut Baumgartner; Volkmar Falk; Jeroen J Bax; Michele De Bonis; Christian Hamm; Per Johan Holm; Bernard Iung; Patrizio Lancellotti; Emmanuel Lansac; Daniel Rodriguez Muñoz; Raphael Rosenhek; Johan Sjögren; Pilar Tornos Mas; Alec Vahanian; Thomas Walther; Olaf Wendler; Stephan Windecker; Jose Luis Zamorano Journal: Eur Heart J Date: 2017-09-21 Impact factor: 29.983
Authors: Yan Topilsky; Simon Maltais; Jose Medina Inojosa; Didem Oguz; Hector Michelena; Joseph Maalouf; Douglas W Mahoney; Maurice Enriquez-Sarano Journal: JACC Cardiovasc Imaging Date: 2018-08-15
Authors: Georg Nickenig; Marcel Weber; Robert Schueler; Jörg Hausleiter; Michael Näbauer; Ralph S von Bardeleben; Efthymios Sotiriou; Ulrich Schäfer; Florian Deuschl; Karl-Heinz Kuck; Felix Kreidel; Jean-Michel Juliard; Eric Brochet; Azeem Latib; Eustachio Agricola; Stephan Baldus; Kai Friedrichs; Prashanthi Vandrangi; Patrick Verta; Rebecca T Hahn; Francesco Maisano Journal: J Am Coll Cardiol Date: 2019-04-23 Impact factor: 24.094
Authors: Mathias Orban; Karl-Philipp Rommel; Edwin C Ho; Matthias Unterhuber; Alberto Pozzoli; Kim A Connelly; Simon Deseive; Christian Besler; Geraldine Ong; Daniel Braun; Jeremy Edwards; Mizuki Miura; Gökhan Gülmez; Lukas Stolz; Mara Gavazzoni; Michel Zuber; Martin Orban; Michael Nabauer; Francesco Maisano; Holger Thiele; Steffen Massberg; Maurizio Taramasso; Neil P Fam; Philipp Lurz; Jörg Hausleiter Journal: JACC Heart Fail Date: 2020-04 Impact factor: 12.035
Authors: Anna Polewczyk; Wojciech Jacheć; Dorota Nowosielecka; Andrzej Tomaszewski; Wojciech Brzozowski; Dorota Szczęśniak-Stańczyk; Krzysztof Duda; Andrzej Kutarski Journal: J Clin Med Date: 2021-12-24 Impact factor: 4.241
Authors: Andrea Simone Deichl; Philipp Lacour; Evgeny Belyavskiy; Burkert Pieske; Elisabeth Pieske-Kraigher; Florian Blaschke; Matthias Schneider Journal: Front Cardiovasc Med Date: 2021-06-04